AbCellera Biologics Inc vs Baidu Inc — how do they compare? AbCellera Biologics Inc trades at $9.2 (market cap $2.99B), while Baidu Inc trades at $104.72 (market cap $36.18B). The key difference: Baidu Inc is far larger — about 12.1× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Baidu Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | BIDU | |
|---|---|---|
Market Cap | $2.99B | $36.18B |
Sector | Health | Media |
52-Week High | $9.76 | $162.52 |
52-Week Low | $2.78 | $86.76 |
Enterprise Value | $2.58B | $32.81B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Baidu (BIDU) trades at $109.50, down 0.19% on the day, with technicals indicating a bearish trend and key support at $108. The company reported a sharp decline in net income to $5.59 billion in 2025, with margins contracting, though it beat EPS estimates in two of the last three quarters. Recent news highlights autonomous vehicle testing in London and a planned Q2 2026 earnings report on August 18, 2026.
The outlook is mixed: strong analyst buy ratings (75.47%) and a $169.80 price target suggest upside, but bearish technicals, profit margin pressures, and China market risks pose challenges. Investment opportunity hinges on AI and cloud growth offsetting advertising weakness, while risks include execution missteps and regulatory headwinds.
Trailing returns across standard periods
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →Baidu, Inc. operates an Internet search engine. The Company offers algorithmic search, enterprise search, news, MP3, and image searches, voice assistance, online storage, and navigation services. Baidu serves clients globally.
Read more on BIDU →